Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo

Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.
Latest website image capture
Clouds background image

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page

  1. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:30:34.000Z thumbnail image
  2. Check
    15 days ago
    No Change Detected
  3. Check
    22 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed study information regarding pembrolizumab and its associated protocols, while adding a new identifier and a revision number.
    Difference
    30%
    Check dated 2025-04-16T20:42:04.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T16:00:35.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-02T00:40:49.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T23:13:04.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T16:44:53.000Z thumbnail image

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo

Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.